<DOC>
	<DOCNO>NCT00003254</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Ethynyluracil may help fluorouracil kill cancer cell make tumor cell sensitive drug . PURPOSE : Phase II trial study effectiveness fluorouracil plus ethynyluracil treating patient advance colorectal cancer respond fluorouracil .</brief_summary>
	<brief_title>SWOG-S9635 Fluorouracil Plus Ethynyluracil Advanced Colorectal Cancer Not Responded Fluorouracil</brief_title>
	<detailed_description>OBJECTIVES : I. Assess confirm response rate fluorouracil ( 5-FU ) plus ethynyluracil ( 776C85 ) patient metastatic colorectal cancer demonstrate resistant 5-FU . II . Assess time progression survival group patient . III . Assess frequency severity toxicity associate treatment . OUTLINE : Patients stratify accord relapse receiving adjuvant therapy ( relapse within 12 month complete adjuvant therapy v relapse receive adjuvant therapy ) . Patients receive oral dos ethynyluracil ( 776C85 ) fluorouracil twice daily 28 day follow 1 week rest . Treatment continue every 5 week absence disease progression unacceptable toxicity . Patients follow every 3 month first year , every 4 month second year , every 6 month thereafter . PROJECTED ACCRUAL : A total 35-75 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Eniluracil</mesh_term>
	<criteria>Histologically cytologically proven metastatic colorectal cancer Prior surgery require No prior treatment metastatic disease Disease progression fluorouracil adjuvant therapy Bidimensionally measurable disease Age : Over 18 Performance status : SWOG 02 Hematopoietic : Platelet count least 100,000/mm3 , Absolute granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 3 time ULN ( great 5 time ULN liver involvement ) Renal : Creatinine clearance least 50 mL/min Other : Must able swallow retain oral medication No nutritional support gastrostomy feed tube parenteral support No intractable vomit nausea Patients history prior malignancy must currently disease free therapy malignancy Not pregnant nursing Fertile patient must use effective contraception Biologic therapy : No concurrent immunotherapy Chemotherapy ; At least 3 week since prior chemotherapy recover ; No concurrent flucytosine ; No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : Prior adjuvant pelvic radiation radiation one area recurrence allow At least 4 week since prior radiotherapy recover Total area bone marrow irradiation must exceed 25 % No concurrent radiotherapy Surgery : At least 2 week since prior surgery colorectal cancer recover No prior resection stomach small intestine Other : No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>